Email updates

Keep up to date with the latest news and content from BMC Medicine and BioMed Central.

Journal App

google play app store
Open Access Correction

Correction: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

Clifford J Bailey1*, Jorge L Gross2, Delphine Hennicken3, Nayyar Iqbal4, Traci A Mansfield4 and James F List4

Author Affiliations

1 Life and Health Sciences, Aston University, Birmingham B4 7ET, UK

2 Endocrine Division, Universidade Federal do Rio Grande do Sul, Avenida Paulo Gama 110-Reitoria, Porto Alegre 90040-060, Brazil

3 Global Biometric Services, Bristol-Myers Squibb, Parc de l’Alliance, Avenue de Finlande 4, Braine I’Alleud B-1420, Belgium

4 Global Clinical Research, Bristol-Myers Squibb, Route 206 & Province Line Road, Princeton, NJ 08543, USA

For all author emails, please log on.

BMC Medicine 2013, 11:193  doi:10.1186/1741-7015-11-193

The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1741-7015/11/193


Received:20 August 2013
Accepted:20 August 2013
Published:2 September 2013

© 2013 Bailey et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Correction

The authors [1] note that the standard errors in Table 3 (Table 1 here) are actually standard deviations. The reference to standard errors in the footnote has now been edited accordingly.

This is a Correction article on http://www.biomedcentral.com/1741-7015/11/43 webcite.

Table 1. Summary of laboratory parameters

References

  1. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.

    BMC Medicine 2013, 11:43. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1741-7015/11/193/prepub